

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 JAN 27 Source of Registration (SR) information in REGISTRY updated  
and searchable  
NEWS 4 JAN 27 A new search aid, the Company Name Thesaurus, available in  
CA/CAPLUS  
NEWS 5 FEB 05 German (DE) application and patent publication number format  
changes  
NEWS 6 MAR 03 MEDLINE and LMEADLINE reloaded  
NEWS 7 MAR 03 MEDLINE file segment of TOXCENTER reloaded  
NEWS 8 MAR 03 FRANCEPAT now available on STN  
NEWS 9 MAR 29 Pharmaceutical Substances (PS) now available on STN  
NEWS 10 MAR 29 WPIFV now available on STN  
NEWS 11 MAR 29 No connect hour charges in WPIFV until May 1, 2004  
NEWS 12 MAR 29 New monthly current-awareness alert (SDI) frequency in RAPRA  
  
NEWS EXPRESS MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 13 APRIL 2004  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 10:32:57 ON 26 APR 2004

=> file medline, uspatful, biosis, wpids, japio, fsta, jicst, biobusiness,  
scisearch, ceaba, cen, embase, dgene  
COST IN U.S. DOLLARS

	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 10:33:36 ON 26 APR 2004

FILE 'USPATFULL' ENTERED AT 10:33:36 ON 26 APR 2004  
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 10:33:36 ON 26 APR 2004  
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'WPIDS' ENTERED AT 10:33:36 ON 26 APR 2004  
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'JAPIO' ENTERED AT 10:33:36 ON 26 APR 2004  
COPYRIGHT (C) 2004 Japanese Patent Office (JPO)- JAPIO

FILE 'FSTA' ENTERED AT 10:33:36 ON 26 APR 2004  
COPYRIGHT (C) 2004 International Food Information Service

FILE 'JICST-EPLUS' ENTERED AT 10:33:36 ON 26 APR 2004  
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'BIOBUSINESS' ENTERED AT 10:33:36 ON 26 APR 2004  
COPYRIGHT (C) 2004 Biological Abstracts, Inc. (BIOSIS)

FILE 'SCISEARCH' ENTERED AT 10:33:36 ON 26 APR 2004  
COPYRIGHT 2004 THOMSON ISI

FILE 'CEABA-VTB' ENTERED AT 10:33:36 ON 26 APR 2004  
COPYRIGHT (c) 2004 DECHEMA eV

FILE 'CEN' ENTERED AT 10:33:36 ON 26 APR 2004  
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'EMBASE' ENTERED AT 10:33:36 ON 26 APR 2004  
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'DGENE' ENTERED AT 10:33:36 ON 26 APR 2004  
COPYRIGHT (C) 2004 THOMSON DERWENT

=> s albumin fusion protein () antibody  
L1 6 ALBUMIN FUSION PROTEIN (W) ANTIBODY

=> d l1 ti abs ibib tot

L1 ANSWER 1 OF 6 USPATFULL on STN  
TI Albumin fusion proteins  
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:13611 USPATFULL  
TITLE: Albumin fusion proteins  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010134	A1	20040115
APPLICATION INFO.:	US 2001-833245	A1	20010412 (9)

NUMBER	DATE
--------	------

-----

PRIORITY INFORMATION: US 2000-256931P 20001221 (60)  
US 2000-199384P 20000425 (60)  
US 2000-229358P 20000412 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 29  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 18 Drawing Page(s)  
LINE COUNT: 25066  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 2 OF 6 USPATFULL on STN  
TI Albumin fusion proteins  
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:312278 USPATFULL  
TITLE: Albumin fusion proteins  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003219875	A1	20031127
APPLICATION INFO.:	US 2001-833118	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 29  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 18 Drawing Page(s)  
LINE COUNT: 15415  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 3 OF 6 USPATFULL on STN  
TI Albumin fusion proteins  
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion

proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:282700 USPATFULL  
TITLE: Albumin fusion proteins  
INVENTOR(S): Ballance, David J., Berwyn, PA, UNITED STATES  
Sleep, Darrell, West Bridgford, UNITED KINGDOM  
Prior, Christopher P., Rosemont, PA, UNITED STATES  
Sadeghi, Homayoun, Doylestown, PA, UNITED STATES  
Turner, Andrew J., Eagleville, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003199043	A1	20031023
APPLICATION INFO.:	US 2001-832501	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 60  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 18 Drawing Page(s)  
LINE COUNT: 14339

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 4 OF 6 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:244853 USPATFULL  
TITLE: Albumin fusion proteins  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Sadeghi, Homayoun, Doylestown, PA, UNITED STATES  
Prior, Christopher P., Rosemont, PA, UNITED STATES  
Turner, Andrew J., Eagleville, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003171267	A1	20030911
APPLICATION INFO.:	US 2001-833117	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 59  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 20 Drawing Page(s)  
LINE COUNT: 13208  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 5 OF 6 USPATFULL on STN  
TI Chemokine beta-1 fusion proteins  
AB The present invention relates to novel chemokine polypeptides and encoding nucleic acids. More specifically, therapeutic compositions and methods are provided using isolated nucleic acid molecules encoding a human chemokine beta-1 (Ck $\beta$ -1 or Ckb1) polypeptide (previously termed monocyte-colony inhibitory factor (M-CIF), MIP1- $\gamma$ , and Hemofiltrate CC chemokine-1 (HCC-1)), and Ckb1 polypeptides themselves, as are vectors, host cells and recombinant methods for producing the same. Also provided are methods of treating, preventing, ameliorating diseases using such compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:206834 USPATFULL  
TITLE: Chemokine beta-1 fusion proteins  
INVENTOR(S): Bell, Adam, Germantown, MD, UNITED STATES  
Ruben, Steven M., Olney, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003143191	A1	20030731
APPLICATION INFO.:	US 2002-153604	A1	20020524 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-293212P	20010525 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	21 Drawing Page(s)	
LINE COUNT:	15446	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 6 OF 6 USPATFULL on STN  
TI Albumin fusion proteins  
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:181414 USPATFULL  
TITLE: Albumin fusion proteins  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 2003125247 A1 20030703  
APPLICATION INFO.: US 2001-833041 A1 20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	20 Drawing Page(s)	
LINE COUNT:	15235	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 10:32:57 ON 26 APR 2004)

FILE 'MEDLINE, USPATFULL, BIOSIS, WPIDS, JAPIO, FSTA, JICST-EPLUS,  
BIOBUSINESS, SCISEARCH, CEABA-VTB, CEN, EMBASE, DGENE' ENTERED AT  
10:33:36 ON 26 APR 2004

L1 6 S ALBUMIN FUSION PROTEIN () ANTIBODY

=> s HER2 antibody

L2 521 HER2 ANTIBODY

=> s albumin fusion protein and l2

L3 0 ALBUMIN FUSION PROTEIN AND L2

=> s albumin fusion protein () HER2 antibody

L4 0 ALBUMIN FUSION PROTEIN (W) HER2 ANTIBODY

=> s human epidermal growth factor receptor 2 adj albumin fusion protein  
10 FILES SEARCHED...

L5 0 HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 ADJ ALBUMIN FUSION  
PROTEIN

=> s human epidermal growth factor

L6 6589 HUMAN EPIDERMAL GROWTH FACTOR

=> s l6 and "receptor-2"

6 FILES SEARCHED...

L7 875 L6 AND "RECEPTOR-2"

=> s l7 and albumin

L8 91 L7 AND ALBUMIN

=> d l8 ti abs ibib 1-10

L8 ANSWER 1 OF 91 USPATFULL on STN

TI Genomics-driven high speed cellular assays, development thereof, and  
collections of cellular reporters

AB Methods for identifying responder genes and regulatory regions that  
confer responsiveness to a test substance or other perturbation are  
provided. Regulatory regions identified by such methods or other methods  
are cloned into expression constructs to control expression of a nucleic  
acid molecule that encodes, for example, a selectable marker or  
reporter, and introduced into cells. The resulting cells are used, for

example, in high throughput screening assays for profiling substances and conditions and for studying the function of the regulatory region mediating the response. Addressable collections of the cells are also provided.

ACCESSION NUMBER: 2004:101092 USPATFULL  
TITLE: Genomics-driven high speed cellular assays, development thereof, and collections of cellular reporters  
INVENTOR(S): Caldwell, Jeremy S., Cardiff, CA, UNITED STATES  
Hogenesch, John B., Encinitas, CA, UNITED STATES  
Su, Andrew I., La Jolla, CA, UNITED STATES  
PATENT ASSIGNEE(S): IRM, LLC (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004076954	A1	20040422
APPLICATION INFO.:	US 2002-97034	A1	20020312 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-275148P	20010312 (60)
	US 2001-274979P	20010312 (60)
	US 2001-275070P	20010312 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HELLER EHRMAN WHITE & MCAULIFFE LLP, 4350 LA JOLLA VILLAGE DRIVE, 7TH FLOOR, SAN DIEGO, CA, 92122-1246  
NUMBER OF CLAIMS: 125  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 2 Drawing Page(s)  
LINE COUNT: 6335

L8 ANSWER 2 OF 91 USPATFULL on STN  
TI Molecular toxicology modeling  
AB The present invention is based on the elucidation of the global changes in gene expression and the identification of toxicity markers in tissues or cells exposed to a known renal toxin. The genes may be used as toxicity markers in drug screening and toxicity assays. The invention includes a database of genes characterized by toxin-induced differential expression that is designed for use with microarrays and other solid-phase probes.

ACCESSION NUMBER: 2004:94708 USPATFULL  
TITLE: Molecular toxicology modeling  
INVENTOR(S): Mendrick, Donna, Gaithersburg, MD, UNITED STATES  
Porter, Mark, Gaithersburg, MD, UNITED STATES  
Johnson, Kory, Gaithersburg, MD, UNITED STATES  
Higgs, Brandon, Gaithersburg, MD, UNITED STATES  
Castle, Arthur, Gaithersburg, MD, UNITED STATES  
Elashoff, Michael, Gaithersburg, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004072160	A1	20040415
APPLICATION INFO.:	US 2002-152319	A1	20020522 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-292335P	20010522 (60)
	US 2001-297523P	20010613 (60)
	US 2001-298925P	20010619 (60)
	US 2001-303810P	20010710 (60)
	US 2001-303807P	20010710 (60)
	US 2001-303808P	20010710 (60)

US 2001-315047P	20010828 (60)
US 2001-324928P	20010927 (60)
US 2001-330867P	20011101 (60)
US 2001-330462P	20011022 (60)
US 2001-331805P	20011121 (60)
US 2001-336144P	20011206 (60)
US 2001-340873P	20011219 (60)
US 2002-357843P	20020221 (60)
US 2002-357842P	20020221 (60)
US 2002-357844P	20020221 (60)
US 2002-364134P	20020315 (60)
US 2002-370206P	20020408 (60)
US 2002-370247P	20020408 (60)
US 2002-370144P	20020408 (60)
US 2002-371679P	20020412 (60)
US 2002-372794P	20020417 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE  
NW, WASHINGTON, DC, 20004  
NUMBER OF CLAIMS: 59  
EXEMPLARY CLAIM: 1  
LINE COUNT: 27909

L8 ANSWER 3 OF 91 USPATFULL on STN  
TI Method for making humanized antibodies  
AB Variant immunoglobulins, particularly humanized antibody polypeptides  
are provided, along with methods for their preparation and use.  
Consensus immunoglobulin sequences and structural models are also  
provided.

ACCESSION NUMBER: 2004:90568 USPATFULL  
TITLE: Method for making humanized antibodies  
INVENTOR(S): Carter, Paul J., San Francisco, CA, United States  
Presta, Leonard G., San Francisco, CA, United States  
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6719971	B1	20040413
APPLICATION INFO.:	US 2000-705392		20001102 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 146206, now patented, Pat. No. US 6407213, issued on 18 Jun 2002 Continuation-in-part of Ser. No. US 1991-715272, filed on 14 Jun 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Ungar, Susan		
ASSISTANT EXAMINER:	Davis, Minh Tam		
LEGAL REPRESENTATIVE:	Lee, Wendy M.		
NUMBER OF CLAIMS:	5		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	9 Drawing Figure(s); 9 Drawing Page(s)		
LINE COUNT:	4948		

L8 ANSWER 4 OF 91 USPATFULL on STN  
TI Central airway administration for systemic delivery of therapeutics  
AB The present invention relates to methods and products for the  
transepithelial systemic delivery of therapeutics. In particular, the  
invention relates to methods and compositions for the systemic delivery  
of therapeutics by administering an aerosol containing antibodies or  
conjugates of a therapeutic agent with an FcRn binding partner to  
epithelium of central airways of the lung. The methods and products are



adaptable to a wide range of therapeutic agents, including proteins and polypeptides, nucleic acids, drugs, and others. In particular embodiments the conjugates are fusion proteins in which a therapeutic polypeptide is joined at its C terminal end through a peptide linker to the N terminal end of an immunoglobulin Fc gamma heavy chain, wherein the linker includes Glycine and Serine residues and is preferably 15 amino acids long. In one embodiment the fusion protein includes an interferon-alpha 2b (IFN- $\alpha$ 2b) joined at its C terminal end through a peptide linker having a sequence Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Ser (SEQ ID NO:29) to the N terminal end of a human Fc $\gamma$ 1 heavy chain. The methods and products have the advantage of not requiring administration to the deep lung in order to effect systemic delivery.

ACCESSION NUMBER: 2004:83456 USPATFULL  
 TITLE: Central airway administration for systemic delivery of therapeutics  
 INVENTOR(S): Blumberg, Richard S., Chestnut Hill, MA, UNITED STATES  
 Lencer, Wayne I., Jamaica Plain, MA, UNITED STATES  
 Simister, Neil E., Wellesley, MA, UNITED STATES  
 Bitonti, Alan J., Acton, MA, UNITED STATES  
 PATENT ASSIGNEE(S): The Brigham and Women's Hospital, Inc., Boston, MA (U.S. corporation)  
 Children's Medical Center Corporation, Boston, MA (U.S. corporation)  
 Brandeis University, Waltham, MA (U.S. corporation)  
 Syntonix Pharmaceuticals, Inc., Waltham, MA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004063912	A1	20040401
APPLICATION INFO.:	US 2003-622108	A1	20030717 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2003-435608, filed on 9 May 2003, PENDING Continuation-in-part of Ser. No. WO 2002-US21335, filed on 3 Jul 2002, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-364482P	20020315 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Alan W. Steele, Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA, 02210	
NUMBER OF CLAIMS:	50	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	17 Drawing Page(s)	
LINE COUNT:	4477	

L8 ANSWER 5 OF 91 USPATFULL on STN

TI Multivalent and multispecific binding proteins, their manufacture and use

AB Polypeptides comprising a first domain, which comprises a binding region of an immunoglobulin heavy chain variable region, and a second domain, which comprises a binding region of an immunoglobulin light chain variable region, the domains being linked but incapable of associating with each other to form an antigen binding site, associate to form antigen binding multimers, such as dimers, which may be multivalent or have multispecificity. The domains may be linked by a short peptide linker or may be joined directly together. Bispecific dimers may have longer linkers. Methods of preparation of the polypeptides and multimers and diverse repertoires thereof, and their display on the surface of bacteriophage for easy selection of binders of interest, are disclosed, along with many utilities.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:76622 USPATFULL  
TITLE: Multivalent and multispecific binding proteins, their  
manufacture and use  
INVENTOR(S): Holliger, Kaspar-Philipp, Cambridge, UNITED KINGDOM  
Griffiths, Andrew David, Cambridge, UNITED KINGDOM  
Hoogenboom, Hendricus Renerus Jacobus Matheus, Hasselt,  
BELGIUM  
Malmqvist, Magnus, Uppsala, SWEDEN  
Marks, James David, Kensington, CA, UNITED STATES  
McGuinness, Brian Timothy, Cambridge, UNITED KINGDOM  
Pope, Anthony Richard, Cambridge, UNITED KINGDOM  
Prospero, Terence Derek, Cambridge, UNITED KINGDOM  
Winter, Gregory Paul, Cambridge, UNITED KINGDOM  
PATENT ASSIGNEE(S): Medical Research Council (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004058400	A1	20040325
APPLICATION INFO.:	US 2002-247839	A1	20020920 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	B. J. Sadoff, NIXON & VANDERHYE, 8th Floor, 1100 North Glebe Road, Arlington, VA, 22201		
NUMBER OF CLAIMS:	61		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	28 Drawing Page(s)		
LINE COUNT:	5361		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 6 OF 91 USPATFULL on STN  
TI Fusion proteins comprising DP-178 and other viral fusion inhibitor  
peptides useful for treating aids  
AB The present invention relates to peptides which exhibit potent  
anti-retroviral activity. The peptides of the invention comprise DP178  
(SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the  
HIV-1.sub.LAI gp41 protein, and fragments, analogs and homologs of  
DP178. The invention further relates to the uses of such peptides as  
inhibitory of human and non-human retroviral, especially HIV,  
transmission to uninfected cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:69593 USPATFULL  
TITLE: Fusion proteins comprising DP-178 and other viral  
fusion inhibitor peptides useful for treating aids  
INVENTOR(S): Bolognesi, Dani Paul, Durham, NC, UNITED STATES  
Matthews, Thomas James, Durham, NC, UNITED STATES  
Wild, Carl T., Durham, NC, UNITED STATES  
Barney, Shawn O'apos, Lin, Cary, NC, UNITED STATES  
Lambert, Dennis Michael, Cary, NC, UNITED STATES  
Petteway, Stephen Robert, Cary, NC, UNITED STATES  
Langlois, Alphonse J., Durham, NC, UNITED STATES  
PATENT ASSIGNEE(S): Duke University (U.S. corporation)  
Trimeris, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004052820	A1	20040318
APPLICATION INFO.:	US 2002-267748	A1	20021008 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-484223, filed on 7 Jun 1995, PENDING Division of Ser. No. US 1995-470896, filed on 6 Jun 1995, GRANTED, Pat. No. US 6479055 Continuation-in-part of Ser. No. US 1994-360107, filed		

on 20 Dec 1994, GRANTED, Pat. No. US 6017536  
Continuation-in-part of Ser. No. US 1994-255208, filed  
on 7 Jun 1994, GRANTED, Pat. No. US 6440656  
Continuation-in-part of Ser. No. US 1993-73028, filed  
on 7 Jun 1993, GRANTED, Pat. No. US 5464933

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: PENNIE AND EDMONDS, 1155 AVENUE OF THE AMERICAS, NEW  
YORK, NY, 100362711  
NUMBER OF CLAIMS: 15  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 83 Drawing Page(s)  
LINE COUNT: 40442  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 7 OF 91 USPATFULL on STN  
TI Methods of immunotherapy and diagnosis  
AB Certain cells, including types of cancer cells such as T-cell lymphoma,  
T-cell leukemia, multiple myeloma, and chronic myeloid leukemia, B cell  
lymphoma of mature B cell lineage, non-Hodgkin's lymphoma of mature  
B-cell lineage, and Burkitt's lymphoma of mature B cell lineage, are  
capable of expressing SEQ ID NO: 2 or 4-encoding RNA. Immunotargeting  
using SEQ ID NO: 2 or 4 polypeptides, nucleic acids encoding for SEQ ID  
NO: 2 or 4 polypeptides and anti-SEQ ID NO: 2 or 4 antibodies provides a  
method of killing or inhibiting that growth of cancer cells that express  
the SEQ ID NO: 2 or 4 protein. Methods of immunotherapy and diagnosis of  
disorders associated with SEQ ID NO: 2 or 4 protein-expressing cells,  
such as T-cell lymphoma, T-cell leukemia, multiple myeloma, and chronic  
myeloid leukemia, B cell lymphoma of mature B cell lineage,  
non-Hodgkin's lymphoma of mature B-cell lineage, and Burkitt's lymphoma  
of mature B cell lineage, are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:64298 USPATFULL  
TITLE: Methods of immunotherapy and diagnosis  
INVENTOR(S): Emtage, Peter C.R., Sunnyvale, CA, UNITED STATES  
Tang, Y. Tom, San Jose, CA, UNITED STATES  
Wang, Zhiwei, Sunnyvale, CA, UNITED STATES  
Drmanac, Radoje T., Palo Alto, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004048817	A1	20040311
APPLICATION INFO.:	US 2002-304234	A1	20021126 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-128558, filed on 22 Apr 2002, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-339453P	20011211 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Elena Quertermous, NUVELO, 670 Almanor Avenue, Sunnyvale, CA, 94085	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2808	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 8 OF 91 USPATFULL on STN  
TI Gene expression in bladder tumors  
AB Methods for analyzing tumor cells, particularly bladder tumor cells  
employ gene expression analysis of samples. Gene expression patterns are  
formed and compared to reference patterns. Alternatively gene expression

patterns are manipulated to exclude genes which are expressed in contaminating cell populations. Another alternative employs subtraction of the expression of genes which are expressed in contaminating cell types. These methods provide improved accuracy as well as alternative basis for analysis from diagnostic and prognostic tools currently available.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:50778 USPATFULL  
TITLE: Gene expression in bladder tumors  
INVENTOR(S): Orntoft, Torben F., Aabyhoj, DENMARK

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004038207	A1	20040226
APPLICATION INFO.:	US 2001-951968	A1	20010914 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-510643, filed on 22 Feb 2000, UNKNOWN		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	BANNER & WITCOFF, 1001 G STREET N W, SUITE 1100, WASHINGTON, DC, 20001		
NUMBER OF CLAIMS:	26		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	15 Drawing Page(s)		
LINE COUNT:	28561		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 9 OF 91 USPATFULL on STN  
TI Nucleic acids encoding DP-178 and other viral fusion inhibitor peptides useful for treating aids  
AB The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1.sub.LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:44245 USPATFULL  
TITLE: Nucleic acids encoding DP-178 and other viral fusion inhibitor peptides useful for treating aids  
INVENTOR(S): Bolognesi, Dani Paul, Durham, NC, UNITED STATES  
Matthews, Thomas James, Durham, NC, UNITED STATES  
Wild, Carl T., Durham, NC, UNITED STATES  
PATENT ASSIGNEE(S): Duke University (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004033235	A1	20040219
APPLICATION INFO.:	US 2003-267682	A1	20030106 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-484223, filed on 7 Jun 1995, PENDING Division of Ser. No. US 1995-470896, filed on 6 Jun 1995, GRANTED, Pat. No. US 6479055 Continuation-in-part of Ser. No. US 1994-360107, filed on 20 Dec 1994, GRANTED, Pat. No. US 6017536 Continuation-in-part of Ser. No. US 1994-255208, filed on 7 Jun 1994, GRANTED, Pat. No. US 6440656 Continuation-in-part of Ser. No. US 1993-73028, filed on 7 Jun 1993, GRANTED, Pat. No. US 5464933		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	PENNIE AND EDMONDS, 1155 AVENUE OF THE AMERICAS, NEW		

YORK, NY, 100362711

NUMBER OF CLAIMS: 15  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 63 Drawing Page(s)  
LINE COUNT: 59510  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 10 OF 91 USPATFULL on STN  
TI Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins  
AB Certain cells, including types of cancer cells such as B-cell lymphomas, T cell lymphomas, Hodgkin's disease and myeloid leukemias, are capable of expressing Toll-like Receptor 9 (TLR9) or Toll-like Receptor 10 (TLR10) mRNA. Immunotargeting using TLR9 or TLR10 polypeptides, nucleic acids encoding for TLR9 or TLR10 polypeptides and anti-TLR9 or anti-TLR10 antibodies provides a method of killing or inhibiting that growth of cancer cells that express the TLR9 or TLR10 protein. Methods of immunotherapy and diagnosis of disorders associated with TLR9 or TLR10 protein-expressing cells, such as B-cell lymphoma, T cell lymphoma, acute myeloid leukemia, Hodgkin's disease, B cell leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia and myelodysplastic syndromes, are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:31728 USPATFULL  
TITLE: Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins  
INVENTOR(S): Dederer, Douglas, Castro Valley, CA, UNITED STATES  
Emtage, Peter C.R., Sunnyvale, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004023870	A1	20040205
APPLICATION INFO.:	US 2002-327491	A1	20021219 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-302444, filed on 22 Nov 2002, PENDING Continuation-in-part of Ser. No. US 2002-77676, filed on 14 Feb 2002, PENDING Continuation-in-part of Ser. No. US 2000-687527, filed on 12 Oct 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-488725, filed on 21 Jan 2000, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Renee S. Polizotto, 675 Almanor Avenue, Sunnyvale, CA, 94085		
NUMBER OF CLAIMS:	25		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	7 Drawing Page(s)		
LINE COUNT:	3553		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 10:32:57 ON 26 APR 2004)

FILE 'MEDLINE, USPATFULL, BIOSIS, WPIDS, JAPIO, FSTA, JICST-EPLUS, BIOBUSINESS, SCISEARCH, CEABA-VTB, CEN, EMBASE, DGENE' ENTERED AT 10:33:36 ON 26 APR 2004

L1 6 S ALBUMIN FUSION PROTEIN () ANTIBODY  
L2 521 S HER2 ANTIBODY  
L3 0 S ALBUMIN FUSION PROTEIN AND L2  
L4 0 S ALBUMIN FUSION PROTEIN () HER2 ANTIBODY  
L5 0 S HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 ADJ ALBUMIN FUSION P  
L6 6589 S HUMAN EPIDERMAL GROWTH FACTOR

L7 875 S L6 AND "RECEPTOR-2"  
L8 91 S L7 AND ALBUMIN

=> s l8 and fusion protein  
L9 77 L8 AND FUSION PROTEIN

=> s l9 and albumin fusion protein  
L10 0 L9 AND ALBUMIN FUSION PROTEIN

=> e rosen, craig/au  
E1 1 ROSEN ZWEIG J/AU  
E2 1 ROSEN ZWEIG JAMES/AU  
E3 0 --> ROSEN, CRAIG/AU  
E4 1 ROSENA BRUCE R/AU  
E5 1 ROSENABUM S/AU  
E6 1 ROSENACKER A F/AU  
E7 1 ROSENACKER ARTHUR F/AU  
E8 4 ROSENADA CEPERO R/AU  
E9 1 ROSENAGER L/AU  
E10 2 ROSENAK B/AU  
E11 73 ROSENAK B D/AU  
E12 31 ROSENAK D/AU

=> e haseltine, W/au  
E1 85 HASELTINE WILLIAM A/AU  
E2 2 HASELTINE WILLIAM ALAN/AU  
E3 0 --> HASELTINE, W/AU  
E4 1 HASELTLINE F P/AU  
E5 8 HASELTON A/AU  
E6 3 HASELTON AARON/AU  
E7 1 HASELTON B J/AU  
E8 4 HASELTON C/AU  
E9 1 HASELTON C B/AU  
E10 9 HASELTON C J/AU  
E11 37 HASELTON C L/AU  
E12 2 HASELTON CAROLE J/AU

=> s e1  
L11 85 "HASELTINE WILLIAM A"/AU

=> s e2  
L12 2 "HASELTINE WILLIAM ALAN"/AU

=> s l11 and "HER2"  
L13 0 L11 AND "HER2"

=> s l12 ti abs ibib tot  
MISSING OPERATOR L12 TI  
The search profile that was entered contains terms or  
nested terms that are not separated by a logical operator.

=> d l12 ti abs ibib tot

L12 ANSWER 1 OF 2 USPATFULL on STN  
TI Nucleic acid encoding HIV-1 tat protein  
AB Nucleic acid encoding a functional HTLV-III/LAV (HIV-1) protein having  
trans-activating ability, and expression vectors comprising this nucleic  
acid are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
ACCESSION NUMBER: 1998:104629 USPATFULL  
TITLE: Nucleic acid encoding HIV-1 tat protein  
INVENTOR(S): Haseltine, William Alan, Cambridge, MA,  
United States

PATENT ASSIGNEE(S): Rosen, Craig A., Brookline, MA, United States  
 Sodroski, Joseph Gerald, Cambridge, MA, United States  
 Wong-Staal, Flossie, San Diego, CA, United States  
 Arya, Suresh K., Gaithersburg, MD, United States  
 Dana-Farber Cancer Institute, Boston, MA, United States  
 (U.S. corporation)  
 The United States of America as represented by the  
 Department of Health and Human Services, Washington,  
 DC, United States (U.S. government)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5801056		19980901
APPLICATION INFO.:	US 1993-131898		19931005 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1992-869053, filed on 14 Apr 1992, now abandoned And a continuation-in-part of Ser. No. US 1988-172152, filed on 23 Mar 1988, now abandoned which is a continuation-in-part of Ser. No. US 1985-780925, filed on 27 Sep 1985, now abandoned, said Ser. No. US -869053 which is a continuation of Ser. No. US 1990-604607, filed on 26 Oct 1990, now abandoned which is a division of Ser. No. US 1985-806263, filed on 6 Dec 1985, now patented, Pat. No. US 4981790		

	NUMBER	DATE
PRIORITY INFORMATION:	CA 1985-482374	19850524
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Fleisher, Mindy	
ASSISTANT EXAMINER:	Railey, II, Johnny F.	
LEGAL REPRESENTATIVE:	Conlin, David G., Eisenstein, Ronald I. Dike, Bronstein, Roberts & Cushman, LLP	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	14 Drawing Figure(s); 7 Drawing Page(s)	
LINE COUNT:	855	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L12 ANSWER 2 OF 2 USPATFULL on STN  
 TI Assay methods for tat cell lines  
 AB Assays screened for compounds that inhibit tat transactivation of the HIV (HTLV-III) LTR are taught. The assay involves tranfecting a cell line containing the tat gene by a vector containing a gene under the control of an HIV-1 LTR, adding the compound to be screened and determining the effect of the compound by looking at the effect of tat as measured by the expression of the gene under the control of the HIV LTR.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 ACCESSION NUMBER: 1998:104559 USPATFULL  
 TITLE: Assay methods for tat cell lines  
 INVENTOR(S): Haseltine, William Alan, Cambridge, MA, United States  
 Rosen, Craig A., Brookline, MA, United States  
 Sodroski, Joseph Gerald, Cambridge, MA, United States  
 Goh, Wei Chun, Somerville, MA, United States  
 PATENT ASSIGNEE(S): Dana Farber Cancer Institute, Boston, MA, United States  
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5800986		19980901
APPLICATION INFO.:	US 1995-456346		19950601 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-213368, filed on 14 Mar 1994, now abandoned which is a continuation of Ser. No. US 1992-869053, filed on 14 Apr 1992, now abandoned which is a continuation of Ser. No. US 1990-604607, filed on 26 Oct 1990, now abandoned which is a division of Ser. No. US 1985-806263, filed on 6 Dec 1985, now patented, Pat. No. US 4981790 which is a continuation-in-part of Ser. No. US 1984-614297, filed on 25 May 1984, now patented, Pat. No. US 4738922

	NUMBER	DATE
PRIORITY INFORMATION:	CA 1985-432374	19850524
	WO 1985-US985	19850524
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Elliott, George C.	
ASSISTANT EXAMINER:	McKelvey, Terry A.	
LEGAL REPRESENTATIVE:	Conlin, David C., Eisenstein, Ronald I. Dike, Bronstein, Roberts & Cushman, LLP	
NUMBER OF CLAIMS:	8	
EXEMPLARY CLAIM:	8	
NUMBER OF DRAWINGS:	14 Drawing Figure(s); 7 Drawing Page(s)	
LINE COUNT:	871	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 10:32:57 ON 26 APR 2004)

FILE 'MEDLINE, USPATFULL, BIOSIS, WPIDS, JAPIO, FSTA, JICST-EPLUS, BIOBUSINESS, SCISEARCH, CEABA-VTB, CEN, EMBASE, DGENE' ENTERED AT 10:33:36 ON 26 APR 2004

L1 6 S ALBUMIN FUSION PROTEIN () ANTIBODY  
L2 521 S HER2 ANTIBODY  
L3 0 S ALBUMIN FUSION PROTEIN AND L2  
L4 0 S ALBUMIN FUSION PROTEIN () HER2 ANTIBODY  
L5 0 S HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 ADJ ALBUMIN FUSION P  
L6 6589 S HUMAN EPIDERMAL GROWTH FACTOR  
L7 875 S L6 AND "RECEPTOR-2"  
L8 91 S L7 AND ALBUMIN  
L9 77 S L8 AND FUSION PROTEIN  
L10 0 S L9 AND ALBUMIN FUSION PROTEIN  
E ROSEN, CRAIG/AU  
E HASELTINE, W/AU  
L11 85 S E1  
L12 2 S E2  
L13 0 S L11 AND "HER2"

=> s l11 and l1

L14 3 L11 AND L1

=> d l14 ti abs ibib ott

'OTT' IS NOT A VALID FORMAT FOR FILE 'USPATFULL'

The following are valid formats:

The default display format is STD.

ABS ----- AB

ALL ----- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD,  
RLI, PRAI, DT, FS, REP, REN, EXNAM, LREP, CLMN, ECL,  
DRWN, AB, GOVI, PARN, SUMM, DRWD, DETD, CLM, INCL,



INCLM, INCLS, NCL, NCLM, NCLS, IC, ICM, ICS,  
EXF, ARTU

ALLG ----- ALL plus PAGE.DRAW

BIB ----- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD, RLI,  
PRAI, DT, FS, EXNAM, LREP, CLMN, ECL, DRWN, LN.CNT

BIB.EX ----- BIB for original and latest publication

BIBG ----- BIB plus PAGE.DRAW

BROWSE ----- See "HELP BROWSE" or "HELP DISPLAY BROWSE". BROWSE must  
entered on the same line as DISPLAY, e.g., D BROWSE.

CAS ----- OS, CC, SX, ST, IT

CBIB ----- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PRAI, DT, FS

DALL ----- ALL, delimited for post-processing

FP ----- PI, TI, IN, INA, PA, PAA, PAT, PTERM, DCD, AI, RLI,  
PRAI, IC, ICM, ICS, INCL, INCLM, INCLS, NCL,  
NCLM, NCLS, EXF, REP, REN, ARTU, EXNAM, LREP,  
CLMN, DRWN, AB

FP.EX ----- FP for original and latest publication

FPALL ----- PI, TI, IN, INA, PA, PAA, PAT, PTERM, DCD, AI,  
RLI, PRAI, IC, ICM, ICS, INCL, INCLM, INCLS, NCL, NCLM,  
NCLS, EXF, REP, REN, ARTU, EXNAM, LREP, CLMN, DRWN, AB,  
PARN, SUMM, DRWD, DETD, CLM

FPBIB ----- PI, TI, IN, INA, PA, PAA, PAT, PTERM, DCD, AI,  
RLI, PRAI, REP, REN, EXNAM, LREP, CLM, CLMN, DRWN

PHITSTR ---- HIT RN, its text modification, its CA index name, and  
its structure diagram

FPG ----- FP plus PAGE.DRAW

GI ----- PN and page image numbers

HIT ----- All fields containing hit terms

HITRN ----- HIT RN and its text modification

HITSTR ----- HIT RN, its text modification, its CA index name, and  
its structure diagram

IABS ----- ABS, indented with text labels

IALL ----- ALL, indented with text labels

IALLG ----- IALL plus PAGE.DRAW

IBIB ----- BIB, indented with text labels

IBIB.EX ---- IBIB for original and latest publication

IBIBG ----- IBIB plus PAGE.DRAW

IMAX ----- MAX, indented with text labels

IMAX.EX ---- IMAX for original and latest publication

IND ----- INCL, INCLM, INCLS, NCL, NCLM, NCLS, IC, ICM, ICS,  
EXF, ARTU, OS, CC, SX, ST, IT

ISTD ----- STD, indented with text labels

KWIC ----- All hit terms plus 20 words on either side

MAX ----- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD,  
RLI, PRAI, DT, FS, REP, REN, EXNAM, LREP, CLMN, ECL,  
DRWN, AB, GOVI, PARN, SUMM, DRWD, DETD, CLM, INCL,  
INCLM, INCLS, NCL, NCLM, NCLS, IC, ICM, ICS,  
EXF, ARTU OS, CC, SX, ST, IT

MAX.EX ----- MAX for original and latest publication

OCC ----- List of display fields containing hit terms

SBIB ----- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, RLI, PRAI,  
DT, FS, LN.CNT

SCAN ----- AN, TI, NCL, NCLM, NCLS, IC, ICM, ICS (random display  
without answer number. SCAN must be entered on the  
same line as DISPLAY, e.g., D SCAN)

STD ----- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, RLI, PRAI,  
DT, FS, LN.CNT, INCL, INCLM, INCLS, NCL, NCLM, NCLS,  
IC, ICM, ICS, EXF (STD is the default)

STD.EX ----- STD for original and latest publication

TRIAL ----- AN, TI, INCL, INCLM, INCLS, NCL, NCLM, NCLS, IC,  
ICM, ICS

ENTER DISPLAY FORMAT (STD):d his  
'D' IS NOT A VALID FORMAT FOR FILE 'USPATFULL'

'HIS' IS NOT A VALID FORMAT FOR FILE 'USPATFULL'

The following are valid formats:

The default display format is STD.

ABS ----- AB  
ALL ----- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD,  
RLI, PRAI, DT, FS, REP, REN, EXNAM, LREP, CLMN, ECL,  
DRWN, AB, GOVI, PARN, SUMM, DRWD, DETD, CLM, INCL,  
INCLM, INCLS, NCL, NCLM, NCLS, IC, ICM, ICS,  
EXF, ARTU  
ALLG ----- ALL plus PAGE.DRAW  
BIB ----- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD, RLI,  
PRAI, DT, FS, EXNAM, LREP, CLMN, ECL, DRWN, LN.CNT  
BIB.EX ----- BIB for original and latest publication  
BIBG ----- BIB plus PAGE.DRAW  
BROWSE ----- See "HELP BROWSE" or "HELP DISPLAY BROWSE". BROWSE must  
entered on the same line as DISPLAY, e.g., D BROWSE.  
CAS ----- OS, CC, SX, ST, IT  
CBIB ----- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PRAI, DT, FS  
DALL ----- ALL, delimited for post-processing  
FP ----- PI, TI, IN, INA, PA, PAA, PAT, PTERM, DCD, AI, RLI,  
PRAI, IC, ICM, ICS, INCL, INCLM, INCLS, NCL,  
NCLM, NCLS, EXF, REP, REN, ARTU, EXNAM, LREP,  
CLMN, DRWN, AB  
FP.EX ----- FP for original and latest publication  
FPALL ----- PI, TI, IN, INA, PA, PAA, PAT, PTERM, DCD, AI,  
RLI, PRAI, IC, ICM, ICS, INCL, INCLM, INCLS, NCL, NCLM,  
NCLS, EXF, REP, REN, ARTU, EXNAM, LREP, CLMN, DRWN, AB,  
PARN, SUMM, DRWD, DETD, CLM  
FPBIB ----- PI, TI, IN, INA, PA, PAA, PAT, PTERM, DCD, AI,  
RLI, PRAI, REP, REN, EXNAM, LREP, CLM, CLMN, DRWN  
PHITSTR ---- HIT RN, its text modification, its CA index name, and  
its structure diagram  
FPG ----- FP plus PAGE.DRAW  
GI ----- PN and page image numbers  
HIT ----- All fields containing hit terms  
HITRN ----- HIT RN and its text modification  
HITSTR ----- HIT RN, its text modification, its CA index name, and  
its structure diagram  
IABS ----- ABS, indented with text labels  
IALL ----- ALL, indented with text labels  
IALLG ----- IALL plus PAGE.DRAW  
IBIB ----- BIB, indented with text labels  
IBIB.EX ---- IBIB for original and latest publication  
IBIBG ----- IBIB plus PAGE.DRAW  
IMAX ----- MAX, indented with text labels  
IMAX.EX ---- IMAX for original and latest publication  
IND ----- INCL, INCLM, INCLS, NCL, NCLM, NCLS, IC, ICM, ICS,  
EXF, ARTU, OS, CC, SX, ST, IT  
ISTD ----- STD, indented with text labels  
KWIC ----- All hit terms plus 20 words on either side  
MAX ----- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD,  
RLI, PRAI, DT, FS, REP, REN, EXNAM, LREP, CLMN, ECL,  
DRWN, AB, GOVI, PARN, SUMM, DRWD, DETD, CLM, INCL,  
INCLM, INCLS, NCL, NCLM, NCLS, IC, ICM, ICS,  
EXF, ARTU OS, CC, SX, ST, IT  
MAX.EX ----- MAX for original and latest publication  
OCC ----- List of display fields containing hit terms  
SBIB ----- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, RLI, PRAI,  
DT, FS, LN.CNT  
SCAN ----- AN, TI, NCL, NCLM, NCLS, IC, ICM, ICS (random display  
without answer number. SCAN must be entered on the

same line as DISPLAY, e.g., D SCAN)  
STD ----- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, RLI, PRAI,  
DT, FS, LN.CNT, INCL, INCLM, INCLS, NCL, NCLM, NCLS,  
IC, ICM, ICS, EXF (STD is the default)  
STD.EX ----- STD for original and latest publication  
TRIAL ----- AN, TI, INCL, INCLM, INCLS, NCL, NCLM, NCLS, IC,  
ICM, ICS

ENTER DISPLAY FORMAT (STD):end

=> d his

(FILE 'HOME' ENTERED AT 10:32:57 ON 26 APR 2004)

FILE 'MEDLINE, USPATFULL, BIOSIS, WPIDS, JAPIO, FSTA, JICST-EPLUS,  
BIOBUSINESS, SCISEARCH, CEABA-VTB, CEN, EMBASE, DGENE' ENTERED AT  
10:33:36 ON 26 APR 2004

L1 6 S ALBUMIN FUSION PROTEIN () ANTIBODY  
L2 521 S HER2 ANTIBODY  
L3 0 S ALBUMIN FUSION PROTEIN AND L2  
L4 0 S ALBUMIN FUSION PROTEIN () HER2 ANTIBODY  
L5 0 S HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 ADJ ALBUMIN FUSION P  
L6 6589 S HUMAN EPIDERMAL GROWTH FACTOR  
L7 875 S L6 AND "RECEPTOR-2"  
L8 91 S L7 AND ALBUMIN  
L9 77 S L8 AND FUSION PROTEIN  
L10 0 S L9 AND ALBUMIN FUSION PROTEIN  
E ROSEN, CRAIG/AU  
E HASELTINE, W/AU  
L11 85 S E1  
L12 2 S E2  
L13 0 S L11 AND "HER2"  
L14 3 S L11 AND L1

=> d l14 ti abs ibib tot .

L14 ANSWER 1 OF 3 USPATFULL on STN  
TI Albumin fusion proteins  
AB The present invention encompasses albumin fusion proteins. Nucleic acid  
molecules encoding the albumin fusion proteins of the invention are also  
encompassed by the invention, as are vectors containing these nucleic  
acids, host cells transformed with these nucleic acids vectors, and  
methods of making the albumin fusion proteins of the invention and using  
these nucleic acids, vectors, and/or host cells. Additionally the  
present invention encompasses pharmaceutical compositions comprising  
albumin fusion proteins and methods of treating, preventing, or  
ameliorating diseases, disorders or conditions using albumin fusion  
proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:13611 USPATFULL  
TITLE: Albumin fusion proteins  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010134	A1	20040115
APPLICATION INFO.:	US 2001-833245	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)

US 2000-229358P 20000412 (60)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850  
NUMBER OF CLAIMS: 29  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 18 Drawing Page(s)  
LINE COUNT: 25066  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 2 OF 3 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:312278 USPATFULL  
TITLE: Albumin fusion proteins  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003219875	A1	20031127
APPLICATION INFO.:	US 2001-833118	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850  
NUMBER OF CLAIMS: 29  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 18 Drawing Page(s)  
LINE COUNT: 15415  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 3 OF 3 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:181414 USPATFULL  
TITLE: Albumin fusion proteins  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003125247	A1	20030703
APPLICATION INFO.:	US 2001-833041	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	20 Drawing Page(s)	
LINE COUNT:	15235	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

=> d his

(FILE 'HOME' ENTERED AT 10:32:57 ON 26 APR 2004)

FILE 'MEDLINE, USPATFULL, BIOSIS, WPIDS, JAPIO, FSTA, JICST-EPLUS,  
BIOBUSINESS, SCISEARCH, CEABA-VTB, CEN, EMBASE, DGENE' ENTERED AT  
10:33:36 ON 26 APR 2004

L1 6 S ALBUMIN FUSION PROTEIN () ANTIBODY  
L2 521 S HER2 ANTIBODY  
L3 0 S ALBUMIN FUSION PROTEIN AND L2  
L4 0 S ALBUMIN FUSION PROTEIN () HER2 ANTIBODY  
L5 0 S HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 ADJ ALBUMIN FUSION P  
L6 6589 S HUMAN EPIDERMAL GROWTH FACTOR  
L7 875 S L6 AND "RECEPTOR-2"  
L8 91 S L7 AND ALBUMIN  
L9 77 S L8 AND FUSION PROTEIN  
L10 0 S L9 AND ALBUMIN FUSION PROTEIN  
E ROSEN, CRAIG/AU  
E HASELTINE, W/AU  
L11 85 S E1  
L12 2 S E2  
L13 0 S L11 AND "HER2"  
L14 3 S L11 AND L1

=> s l11 and albumin fusion protein  
L15 3 L11 AND ALBUMIN FUSION PROTEIN

=> d l15 ti abs ibib tot

L15 ANSWER 1 OF 3 USPATFULL on STN  
TI Albumin fusion proteins  
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising

albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:13611 USPATFULL  
TITLE: Albumin fusion proteins  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010134	A1	20040115
APPLICATION INFO.:	US 2001-833245	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	18 Drawing Page(s)	
LINE COUNT:	25066	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 2 OF 3 USPATFULL on STN

TI Albumin fusion proteins  
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:312278 USPATFULL  
TITLE: Albumin fusion proteins  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003219875	A1	20031127
APPLICATION INFO.:	US 2001-833118	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	29	

EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 18 Drawing Page(s)  
LINE COUNT: 15415  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 3 OF 3 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:181414 USPATFULL  
TITLE: Albumin fusion proteins  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003125247	A1	20030703
APPLICATION INFO.:	US 2001-833041	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	20 Drawing Page(s)	
LINE COUNT:	15235	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.